NEW YORK Mercer has unveiled its new product, Dx-Rx Pairing, which was developed to encourage patients to use the most appropriate medication for specific conditions and it performs this by reducing drug co-payments for certain diagnosis/drug pairings and increasing educational outreach to participants and providers. The plan only targets these combinations of diagnoses and drug therapies that have been proven medically to improve health while lowering health costs.
The company has found through clinical evidence that, by linking a specific diagnosis with a specific regimen of prescribed drugs, this results in a health status improvement that avoids or reduced other medical costs.
“Today's pharmacy benefit plans typically are designed to reduce drug cost only. They provide little to no monitoring of compliance and miss significant opportunities to improve health,” said David Dross, national leader of Mercer's managed pharmacy consulting group. “Dx-Rx Pairing promotes the use of evidence-based drug therapies that improve enrollee health and reduce total health care spending. This approach can reduce an employer's total health care spending by an estimated 1-2 percentage points.”